Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells $3,670,400.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 37,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00. Following the completion of the sale, the chief executive officer owned 744,709 shares of the company’s stock, valued at $73,875,132.80. The trade was a 4.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Stock Performance

BioNTech stock traded down $0.53 on Wednesday, reaching $98.13. 706,871 shares of the stock were exchanged, compared to its average volume of 1,112,188. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The firm has a fifty day moving average price of $96.94 and a two-hundred day moving average price of $95.55. The stock has a market cap of $24.82 billion, a PE ratio of -12.53 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The business had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s revenue for the quarter was down 59.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.60) earnings per share. Sell-side analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Several hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada grew its position in BioNTech by 95.9% during the first quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock worth $653,000 after buying an additional 3,514 shares in the last quarter. NewEdge Advisors LLC acquired a new position in BioNTech in the 1st quarter valued at approximately $167,000. Russell Investments Group Ltd. raised its holdings in BioNTech by 368,800.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock valued at $1,178,000 after acquiring an additional 11,064 shares in the last quarter. Natixis bought a new stake in shares of BioNTech in the 2nd quarter worth approximately $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in shares of BioNTech by 2.9% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock worth $52,416,000 after acquiring an additional 13,788 shares during the period. Institutional investors own 15.52% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Canaccord Genuity Group lowered their target price on BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a report on Monday, August 31st. Berenberg Bank cut their price target on BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Sanford C. Bernstein reissued a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $126.00.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.